KR20060116422A - Cilostazol composite composition having increasing solubility and process for preparing the same - Google Patents

Abstract

A composition for inhibiting platelet aggregation comprising cilostazol-nicotine amide composite and a process for preparing the same composition are provided to increase the solubility and release speed of cilostazol, and stabilize release rate of the composition. The composition for inhibiting platelet aggregation comprises the cilostazol-nicotine amide composite, wherein the mole ratio of cilostazol and nicotine amide in the composite is 1:0.5-30; the cilostazol-nicotine amide composite is prepared by dissolving cilostazol and nicotine amide at 110-200 deg. C and stirring and cooling the solution, or introducing a mixed solution of cilostazol and nicotine amide into super critical fluid; and the cilostazol in the composite is the crystalline form A or C or amorphous form.

Description

Cilostazol composite composition having increasing solubility and process for preparing the same

Figure 1 compares the hydrogen atom nuclear magnetic resonance ( ¹ H-NMR) spectra of cilostazol and cilostazol-nicotinamide complex according to the present invention.

Figure 2 compares the hydrogen atom nuclear magnetic resonance ( ¹ H-NMR) spectrum of nicotinamide and cilostazol-nicotinamide complex according to the present invention.

3 is a powder X-ray diffraction analysis (PXRD) of cilostazol.

4 is a powder X-ray diffraction analysis (PXRD) of nicotinamide.

5 is a powder X-ray diffraction analysis (PXRD) results of the cilostazol-nicotinamide complex prepared in Example 1. FIG.

6 is a powder X-ray diffraction analysis (PXRD) results of the cilostazol-nicotinamide complex prepared in Example 2. FIG.

7 is a powder X-ray diffraction analysis (PXRD) results of the cilostazol-nicotinamide complex prepared in Example 5. FIG.

8 is a powder X-ray diffraction analysis (PXRD) of the cilostazol-nicotinamide mixture prepared in Comparative Example 1. FIG.

9 is a powder X-ray diffraction analysis (PXRD) of the cilostazol-nicotinamide mixture prepared in Comparative Example 2. FIG.

10 is a differential scanning calorimetry (DSC) curve of the cilostazol-nicotinamide complex and the raw material of Example 2. FIG.

11 is a Fourier transform infrared spectroscopy (FT-IR) spectrum of cilostazol.

12 is a Fourier transform infrared spectroscopy (FT-IR) spectrum of nicotinamide.

13 is a Fourier transform infrared spectroscopy (FT-IR) spectrum of the cilostazol-nicotinamide complex prepared in Example 2. FIG.

FIG. 14 is a molecular model of the minimum energy state for the cilostazol-nicotinamide complex of Example 2. FIG.

FIG. 15 is an elution curve for Examples 3 to 5, Comparative Example 1, and cilostazol as a raw material.

The present invention relates to a cilostazol-nicotinamide complex, and more particularly, to a cilostazol-nicotinamide complex having a mixing ratio of cilostazol and nicotinamide of 1: 0.5 to 30 molar ratio, a method for preparing the complex and the complex It relates to a pharmaceutical composition for inhibiting platelet aggregation containing and a method for producing the same.

The common name of cilostazol is 6- [4- (1-cyclohexyl-1H-tetrazol-5-yl) butoxy] -3,4-dihydro-2 (1H) -quinazolinone, first by Nishi et al. Synthetic [Chem. Pharm. Bull. Vol. 31, 1151-1157 (1983), US Pat. No. 4,277,479. In addition, the physicochemical properties, pharmacological action, drug absorption, distribution, metabolism and clinical application of cilostazol are described in Arzneimittel-Forsch. 35: 1117-1208 (1985). Cilostazol inhibits cell platelet aggregation and is therefore used to treat patients with intermittent claudication. In addition, cilostazol has been reported to increase high density lipoproteins and apolipoproteins in the blood, which are beneficial to the living body [Dawson et al., Circulation Vol. 98, 678-686 (1998). However, these cilostazols differ greatly among individuals in their bioavailability. In other words, the variance coefficient of pharmacokinetic parameters in oral administration of cilostazol is 40-60%, which is highly different among individuals, and this may be due to low solubility of cilostazol, although the exact cause is not known [Bramer et al. ., Cli. Pharmacokinet. Vol 31. 1-11 (1999). These cilostazols also have high biopermeability and are not disturbed by their absorption by efflux transporters such as p-glycoprotein [Toyobuku et al., J. Pharm. Sci. Vol. 91. 2249-2259 (2003). Cilostazol having this feature is the biggest problem of low solubility pharmaceutical and therapeutic. In order to improve the low solubility of cilostazol, attempts to prepare new polymorphic polymorphisms through repeated heating and cooling using DSC have been disclosed in US Pat. No. 6,388,080. However, these attempts can yield traces of the sample but are difficult to use industrially.

The present inventors found that the solubility and dissolution rate of the complex prepared by mixing cilostazol with a pharmaceutically acceptable nicotinamide were increased while continuing the study for improving the solubility of cilostazol. To complete.

Accordingly, an object of the present invention is to provide a cilostazol-nicotinamide complex and a method for preparing the same, which increase the solubility and dissolution rate of cilostazol.

It is still another object of the present invention to provide a pharmaceutical composition for inhibiting platelet aggregation and a method for producing the same, having a stable and excellent dissolution rate by containing the cilostazol-nicotinamide complex.

The present invention relates to a cilostazol-nicotinamide complex, and more particularly, a cilostazol-nicotinamide complex having a mixing ratio of cilostazol and nicotinamide of 1: 0.5 to 30 molar ratio, a method for preparing the same, and containing the complex. It relates to a pharmaceutical composition for inhibiting platelet aggregation and a method for producing the same.

Although the molar ratio of cilostazol and nicotinamide, which are the reactants of the cilostazol-nicotinamide complex according to the present invention, is not critical, the molar ratio of cilostazol to nicotinamide is preferably 1: 0.5 to 0.5. 30, More preferably, it is 1: 1-10, Most preferably, it is 1: 1.

The driving force for forming the composite in the present invention is believed to be due to two factors. One is the interaction between the pi electrons of quinazolinone of cilostazol and the pi electrons of pyridine of nicotinamide, and the other is hydrogen of amide of cilostazol and oxygen of amide of nicotinamide, cilostazol It is a hydrogen bond with hydrogen of quinazolinone and amide of nicotinamide. FIG. 14 is a graphical representation of the molecular model of the minimum energy state (1: 2 molar ratio of cilostazol-nicotinamide complex) to illustrate the above two factors.

The method for preparing the cilostazol-nicotinamide complex according to the present invention consists of melting-cooling a cilostazol and nicotinamide mixture.

The mixture of cilostazol and nicotinamide is stirred at a melting temperature of 110 ° C. to 200 ° C. to ensure uniform mixing, which is rapidly cooled and then ground to separate 30 to 200 mesh particles.

Another method of preparing the cilostazol-nicotinamide complex according to the present invention is

The cilostazol and nicotinamide are dissolved in a solvent and then prepared into fine particles by a supercritical fluid process or a conventional spray drying method.

The solvent may be any solvent capable of dissolving cilostazol and nicotinamide. Preferably, ethanol, dichloromethane, chloroform, ethyl acetate, N, N-dimethylformamide, dimethyl sulfoxide (DMSO), tetrahydrofuran, methanol, isopropanol and the like, or a mixed solvent thereof may be used.

The supercritical fluid process that can be used in the present invention is a supercritical fluid process, for example, the principle of producing particles by precipitation using supercritical carbon dioxide is, firstly, a drug that is relatively less soluble in supercritical carbon dioxide in a conventional organic solvent. After melting, the solution is sprayed into the supercritical carbon dioxide through the nozzle, and the supercritical carbon dioxide penetrates the sprayed particles, causing dilution of the solvent, and the solvent diluted by the carbon dioxide is less soluble than the pure solvent, thereby making the mixture very difficult. The supersaturated state causes the solute to precipitate or recrystallize to form particles. The supercritical carbon dioxide used here is reusable, environmentally friendly, non-explosive, non-toxic and indefinite, making it ideal for use in the production of pharmaceuticals. Particles can be obtained.

The spray drying method that can be used in the present invention includes a method using a spray dryer, a method using a fluidized bed dryer, etc. Among these methods, it is important to control the spray rate. In other words, when the spraying rate is low, the solvent evaporates too fast, and there is a large amount of drug loss. When the spraying rate is fast, the cilostazol-nicotinamide complex is entangled with each other before the solvent evaporates to increase the particle size. Therefore, the spraying rate is preferably sprayed slowly initially, and spraying more and more rapidly over time, the preferred spraying rate is in the range of 2.5 to 15 ml / min. In addition, the temperature during spraying also acts as a major factor affecting the particle size, it is preferable to maintain the air temperature of more than 70 ℃ at the inlet port of the spray dryer, 60 ℃ or more at the outlet port.

The cilostazol of the cilostazol-nicotinamide complex prepared by the production method according to the present invention is characterized in that the crystalline form A, crystalline C or amorphous, cilostazol-nicotine prepared by the melt-cooling method The amide complex was found to have crystalline Form C.

The present invention also relates to a pharmaceutical composition for inhibiting platelet aggregation containing the cilostazol-nicotinamide complex and a method for preparing the same, wherein the cilostazol-nicotinamide complex is included as an essential component, and at least one of It is characterized by containing a pharmaceutically acceptable excipient. The cilostazol content of the cilostazol-nicotinamide complex contained in the pharmaceutical composition is prepared in the same range as the content contained in a conventional cilostazol formulation.

Excipient materials should be selected in relation to the intended dosage form and should be consistent with conventional pharmaceutical practice. For example, for oral administration in the form of tablets or capsules or syrups, the therapeutically active drug component may be combined with any oral non-toxic pharmaceutically acceptable inert excipient such as lactose or starch. Optionally, the pharmaceutical tablet of the present invention may be a binder such as microcrystalline cellulose, gum tragacanth or gelatin, a disintegrant such as alginic acid, a lubricant such as magnesium stearate, a glidant such as colloidal silicon dioxide, a water It also contains sweetening agents such as chromose or saccharin, colorants or flavoring agents such as peppermint or methyl salicylate.

Because of ease of administration, tablets represent the most advantageous oral unit dosage form. If desired, tablets may be coated with sugars, shellac or other enteric coatings by standard aqueous or non-aqueous techniques.

If the drug content is low during tablet production, it is important to ensure uniformity and uniform dissolution rate.The pharmaceutical composition containing the pre-dispersed cilostazol-nicotinamide complex can be directly mixed with other excipients without a wet process. When tableting, the content imbalance can be reduced, so that a stable and excellent dissolution rate can be obtained.

Hereinafter, the present invention will be described in more detail with reference to Examples. However, embodiments of the present invention may be modified in various forms, and the scope of the present invention should not be construed as being limited by the embodiments described below.

Example 1-2 Preparation of Cilostazol-nicotinamide Complex by Melting the Cilostazol and Nicotinamide

The cilostazol and nicotinamide are precisely weighed into the composition shown in Table 1 below, placed in a glass container, heated to 170 ° C. and stirred, and then the molten mixture is quickly poured onto a stainless steel plate placed on ice water containing potassium chloride. This was then solidified. After storage in a silica gel dataator for one day, it was ground using an IKA analysis mill (Staufen, Germany), and particles between 60-120 mesh were aliquoted and used as samples.

TABLE 1

Example 3-6 Preparation of Cilostazol-nicotinamide Complex by Supercritical Fluid Process

To prepare the cilostazol nicotinamide complex using a supercritical fluid process, a mixed solution of cilostazol and nicotinamide having the composition and content shown in Table 2 was prepared.

TABLE 2

First, cilostazol and nicotinamide are dissolved in the solvent or mixed solvent shown in Table 2. The mixed solution was sprayed into a reaction chamber filled with supercritical carbon dioxide at a temperature of 45 ° C. and a pressure of 100 bar to prepare a uniform complex of cilostazol and nicotinamide in a supercritical state.

Example 7 Preparation of Cilostazol-nicotinamide Composite by Spray Drying Method

In order to prepare the cilostazol nicotinamide complex by spray drying, a mixed solution of cilostazol and nicotinamide having the same composition and content as in Example 3 and Example 4 was prepared. Using a spray dryer (Spray Dryer SD-1000, ELELY, Japan), the injection air temperature was prepared at 80 ℃, spray rate 3 ml / min, dry air amount 0.65 m ³ / min, spray air pressure 200 kPa.

Comparative Example 1-2 Preparation of Physical Mixture of Cilostazol and Nicotinamide

Cilostazol and nicotinamide were weighed in the mixing ratios of Table 3 above and mixed for about 3 minutes using mortar and pestle.

 TABLE 3

Example 8 Saturation Solubility Measurement of the Prepared Cilostazol-nicotinamide Complex

In order to measure the saturation solubility of the cilostazol nicotinamide complex prepared according to the present invention, the complex prepared according to Examples 1 to 6 was used as the experimental group, and Comparative Examples 1 and 2 and the raw material cilostazol as the control sample. Using the experiment was carried out as follows.

Excess sample (10 mg as cilostazol) and 10 ml of distilled water are dispersed in a tube and left to stand in a stirrer at a temperature of 37 ° C. and a 60 rpm hot water bath until it is out of supersaturation, and then filtered with a 0.45 μm membrane filter after 24 hours. Dilution with methanol was performed by HPLC and the results are shown in Table 4.

Column: Xterra ^TM RP 18, 5 μm (4.6 * 250 mm)

Mobile phase: 60% acetonitrile solution

Injection volume: 20 μl

Detector: ultraviolet absorbance photometer (254 nm)

Flow rate: 1.5 ml / min

Table 4 Saturation solubility of cilostazol according to Examples 1 to 6 and Comparative Examples 1 and 2

As shown in Table 4, it can be seen that the saturated solubility was increased in Comparative Examples 1 and 2 and the cilostazol of the control (raw material) in Examples 1 to 6. In addition, it can be seen that the cilostazol-nicotinamide complex has a molar ratio of 1: 2 over 1: 1. In particular, in the case of cilostazol-nicotinamide 1: 2 molar ratio complex, saturation solubility increased more than 2 times than that of the control (raw material).

Example 9 Hydrogen Nuclear Magnetic Resonance Spectrum ( ¹ H-NMR) Analysis

The nuclear magnetic resonance spectrum ( ¹ H resonance frequency: 400 MHz, measurement concentration: 3-4 mg / ml, solvent: CD ₃ OD, external reference material: TMS, measurement temperature: 303K) was obtained using JEOL JNM-AL400 (Akishima, Japan). It measured using.

1 is a hydrogen atom nuclear magnetic resonance spectrum for cilostazol and the complex of Example 2. FIG. Of particular note in this spectrum are the peaks occurring at 6.7106 to 6.682 ppm, that is, the unique values of the hydrogen atoms bonded to the 6th, 8th, and 9th carbon atoms of quinazolinone of cilostazol. 2 is a hydrogen atom nuclear magnetic resonance spectrum of the complex of nicotinamide and Example 2 of the hydrogen atom bound to the second carbon atoms of nicotinamide appearing at 9.015ppm, the sixth carbon atoms of nicotinamide appearing at 8.687ppm It is a unique value.

As shown in Figs. 1 and 2 in the composite of the present invention, this peculiar value is obtained by shifting toward the high magnetic field or the low magnetic field, which is the pi electron between the pi electron of quinazolinone of cilostazol and the pi electron of pyridine of nicotinamide. Indicates that there is a send and receive interaction.

Example 10 X-ray diffraction analysis (PXRD analysis) of the prepared cilostazol-nicotinamide complex

PXRD of the cilostazol-nicotinamide complex prepared according to the present invention was measured. X-rays using the composites prepared in Examples 1 and 2 (1: 1, 1: 2 molar ratio) as experimental groups, Comparative Examples 1 and 2 and cilostazol and nicotinamide as raw materials as control samples. Measurement was performed using a diffraction apparatus (D / MAX-2200 Ultima / PC, Japan), and the results are shown in FIGS. 3 to 9.

As in US Pat. No. 6,388,080, Form C crystals of cilostazol form Form A with the most stable diffraction peaks of 9.4, 10.3, 12.9, 15.3, 15.8, 18.8, 19.4, 20.4, 20.8, 22.0, 23.5, and 31.7 °. Unlike, the major X-ray diffraction peaks appear at 8.6, 9.7, 10.1, 13.1, 17.1, 23.7 and 25.7 °. As shown in FIGS. 5 and 6, in the composites prepared in Examples 1 and 2 (1: 1, 1: 2 molar ratio), Crystal C was different from X-ray diffraction (FIG. 3) of the raw material (Crystal A). X-ray diffraction peak of the type was shown. However, as shown in FIGS. 8 and 9, in Comparative Examples 1 and 2 (physical mixture 1: 1, 1: 2 molar ratio), it was found that Form A was present, and due to dilution and coexistence with nicotinamide Its crystallinity was somewhat reduced. Therefore, cilostazol was confirmed that the crystallinity is changed in complex formation with nicotinamide.

As shown in Figure 7, it can be seen that the strong diffraction peak at 12.9 ° of the control (raw material) disappears in the X-ray diffraction of the cilostazol-nicotinamide complex prepared in Example 5. Thus cilostazol was amorphous in the 1:27 molar ratio complex.

Example 11 Differential Scanning Calorimetry (DSC) Analysis of the Prepared Cilostazol-nicotinamide Complex

Thermodynamic changes were observed using DSC (Differential Scanning Calorimeter) to compare with the raw material of the cilostazol-nicotinamide complex prepared according to the present invention.

Specifically, about 3 to 4 mg of the sample was sealed with a cap of several aluminum pans weighed using a micro balance, which was used as an experimental group, and an empty aluminum pan and a cap were used as a control group. The rate of temperature increase was measured at 5 ° C. per minute and replaced with nitrogen gas during the temperature increase process. The DSC instrument used for analysis was DSC S-650 from Scinco Co., Ltd. Thermal analysis is shown in FIG.

As shown in FIG. 10, the endothermic peak of the raw material cilostazol is shown at 160 ° C. and the nicotinamide is shown at 130 ° C., but the composite prepared in Example 2 was located at about 120 ° C., about 10 ° C. lower than their endothermic peak. An endothermic peak appeared.

Example 12 Infrared Absorption Spectrum (FT-IR Analysis) of the Prepared Cilostazol-nicotinamide Complex

The infrared absorption (FT-IR analysis) spectrum of the cilostazol-nicotinamide complex prepared according to the present invention was measured by the Attenuated Total Reflectance method of Bruker FT-IR (Tensor 27, Germanay). FIG. 11 is a spectrum of cilostazol as a raw material, FIG. 12 is a spectrum of nicotinamide, and FIG. 13 is a spectrum of a cilostazol-nicotinamide complex in a 1: 2 molar ratio of Example 2. FIG.

The complex of cilostazol and nicotinamide has been shown to hydrogen bond between hydrogen of amide and oxygen of carbonyl group. As shown in FIG. 13, in the 1: 2 molar ratio complex, the amide absorption band of cilostazol was 3205 wavenumber (cm ^-1 ) to 3162 wavenumber (cm ^-1 ), and the amide absorption band of nicotinamide was 3359 wavenumber (cm ^-1 ). at 3364 wave number (cm ^-1) in, and 1671 wave number (cm ^-1) 1668 wave number in the group is a complex of nicotinamide seen from cilostazol and 1672 wave number (cm ^-1) showing a strong absorption band at (cm ^-1 ). These results indicate that hydrogen bonding between cilostazol and nicotinamide occurred.

Example 13 Dissolution test

The dissolution test was conducted in accordance with the Dissolution Test No. 2 method of the Korean Pharmacopoeia General Test Method. The rotation speed was 100 rpm and the temperature was 37 ± 0.5 ° C. The test solution was prepared by containing 900% of sodium lauryl sulfate (W / V) in 900 ml of the first solution of the disintegration test method. The test solution was taken at predetermined times, filtered through a filter having a pore size of 0.45 탆, diluted with methanol, and the concentration of cilostazol was calculated by liquid chromatography under the same detection conditions as in Example 8. The complexes prepared in Examples 3 to 5 were used as the experimental group specimens, and Comparative Example 1 and the raw material (cilostazol) were used as the control specimens.

As shown in Figure 15, the composite prepared in Examples 3 to 5 shows a faster dissolution rate than Comparative Example 1 and the control (raw material).

Forming a complex with cilostazol and nicotinamide can change physical properties such as crystal form of the drug, from which the cilostazol-nicotinamide complex can be prepared with increased solubility and dissolution rate. In addition, the pharmaceutical composition for inhibiting platelet aggregation containing the complex has the advantage of having a uniform content and excellent and stable dissolution rate.

Claims (8)

A cilostazol-nicotinamide complex having a ratio of cilostazol and nicotinamide of 1: 0.5 to 30 molar ratio. The method of claim 1, A cilostazol-nicotinamide complex having a mixing ratio of cilostazol and nicotinamide in a ratio of 1: 1 to 10 mol. The method of claim 1, The complex is a cilostazol-nicotinamide complex, which is prepared by melting, stirring, and cooling the mixture of cilostazol and nicotinamide at 110 ° C to 200 ° C. The method of claim 1, The complex is a cilostazol-nicotinamide complex, characterized in that prepared by introducing a mixed solution of cilostazol and nicotinamide into the supercritical fluid. The method of claim 1, The complex is cilostazol-nicotinamide complex, characterized in that prepared by spray-drying a mixed solution of cilostazol and nicotinamide. The method according to claim 3 to 5, Cilostazol of the complex is cilostazol-nicotinamide complex, characterized in that the crystalline form A, C or amorphous. The method of claim 3, wherein The cilostazol of the complex is cilostazol-nicotinamide complex, characterized in that Form C. A pharmaceutical composition for inhibiting platelet aggregation, comprising the cilostazol-nicotinamide complex according to claim 1.

Images